Acarbose Shortage: What Providers and Prescribers Need to Know in 2026

While acarbose is not on the FDA's official drug shortage list in 2026, many prescribers have heard from patients who are struggling to fill their acarbose prescriptions locally. This creates a clinical gap that falls on providers to manage — often with little warning. This guide outlines the current supply landscape, how to counsel patients, and when to consider therapeutic substitution.

Clinical Context: Who Is Still on Acarbose in 2026?

Acarbose is an FDA-approved alpha-glucosidase inhibitor indicated as an adjunct to diet and exercise for adults with type 2 diabetes mellitus. Despite the rise of GLP-1 receptor agonists and SGLT2 inhibitors, acarbose retains a niche in specific clinical scenarios:

Patients who cannot tolerate metformin (e.g., renal impairment, significant GI intolerance)

Patients at high hypoglycemia risk who require monotherapy options without insulin-stimulating effects

Post-gastric bypass patients with postprandial hypoglycemia (off-label use)

Patients with predominantly postprandial glucose excursions who prefer oral-only, weight-neutral therapy

Established patients who are well-controlled on their current regimen and prefer to stay the course

Current Supply Situation (2026)

Acarbose is not listed on the FDA Drug Shortages database as of 2026. However, provider offices and pharmacy desks are fielding patient complaints that reflect localized availability gaps. The root causes are structural rather than a discrete supply chain failure:

Acarbose is a low-volume generic; many community pharmacies deprioritize shelf space for low-turnover medications

Brand-name Precose discontinuation removed a reliable inventory anchor for pharmacies that had stocked it for decades

Multiple generics manufacturers mean regional distribution can be inconsistent, with some distributors intermittently low on specific strengths

Therapeutic Alternatives to Consider

When acarbose is unavailable or the patient has difficulty maintaining consistent access, consider the following evidence-based alternatives, matched to the patient's clinical profile:

Miglitol (Glyset) — Same class, comparable mechanism. Note: may also have intermittent availability at some pharmacies

Metformin — First-line per ADA and AACE guidelines; addresses fasting and postprandial glucose; contraindicated if eGFR <30; widely stocked

DPP-4 inhibitors (sitagliptin, linagliptin) — Weight-neutral, postprandial focus, low hypoglycemia risk; good option for older adults or those with metformin intolerance

SGLT2 inhibitors (empagliflozin, dapagliflozin) — Broad glycemic benefit + cardio/renal protection; ADA and AACE 2026 guidelines recommend as preferred add-on for patients with CVD or CKD; widely available

GLP-1 receptor agonists (semaglutide, dulaglutide) — Recommended for patients with obesity, high CVD risk; significant A1C reduction; injectable; cost and prior auth may be barriers

Important Clinical Notes When Switching Away from Acarbose

When transitioning a patient off acarbose, keep these points in mind:

Acarbose does not cause hypoglycemia when used alone. If the patient is on a combination regimen with a sulfonylurea or insulin, reassess the hypoglycemia risk profile after switching.

Patients experiencing hypoglycemia while on acarbose + sulfonylurea or insulin must use dextrose (glucose tablets, dextrose gel) — NOT sucrose — to treat it. Acarbose inhibits sucrose hydrolysis, making cane sugar an unreliable hypoglycemia treatment. Counsel replacements accordingly.

If a patient has been using acarbose off-label for post-gastric bypass hypoglycemia, coordinate with their bariatric surgery team before substituting, as alternatives may not address the underlying dumping physiology as effectively.

How to Help Patients Locate Acarbose Without Switching

If therapeutic substitution isn't warranted, your patients may simply need help locating acarbose at a nearby pharmacy. medfinder for providers is a service that calls pharmacies on behalf of your patients to locate their medication in stock. Patients can reach medfinder directly, without needing a new prescription — they just provide the drug name, strength, and location.

Suggesting medfinder to patients struggling to fill acarbose can save your front desk from fielding repeat calls and bridges the gap while you determine whether a therapeutic change is needed.

Provider Takeaways for 2026

Acarbose is not in formal FDA shortage — but localized stocking gaps are real and patient-impactful

Proactive patient counseling on pharmacy strategy (large chains, mail order, special order) reduces unnecessary clinical escalations

Maintain individualized fallback plans for patients who depend on acarbose for specific clinical reasons (post-bypass, hypoglycemia risk)

SGLT2 inhibitors and DPP-4 inhibitors are the most clinically appropriate and widely available substitutes for most patients in 2026

Related: How to Help Your Patients Find Acarbose in Stock: A Provider's Guide